Dysfunctional Uterine Bleeding, Endometriosis, Leiomyoma, Menorrhagia, Pelvic Pain
Conditions
Keywords
Hysterectomy, Laparoscopy, Robotics
Brief summary
Approximately 600,000 women undergo hysterectomy each year in the United States, of which 12% are laparoscopic. The most common indications for hysterectomy are: symptomatic uterine leiomyomas (40.7%), endometriosis (17.7%), and prolapse (14.5%). The first total laparoscopic hysterectomy was performed by Reich et al in 1988. Many studies have proven that laparoscopic hysterectomy is associated with lower preoperative morbidity, shorter hospital stay, and shorter recovery times than abdominal hysterectomy. The literature has also shown the complication rates for laparoscopic cases are similar to open procedures in the hands of an experienced laparoscopic surgeon. The American Congress of Obstetricians and Gynecologists Committee on Gynecologic Practice state that laparoscopic hysterectomy is an alternative to abdominal hysterectomy for those patients in whom vaginal hysterectomy is not indicated or feasible. The ACOG Committee on Gynecologic Practice site multiple advantages of laparoscopic hysterectomy to abdominal hysterectomy including faster recovery, shorter hospital stay, less blood loss, and fewer abdominal wall/wound infections. Despite the recommendations of ACOG for a more minimally invasive approach, 66% of all hysterectomies are performed abdominally. Key reasons for the lag in utilization of laparoscopic techniques are the technical obstacles of performing minimally invasive hysterectomies. Robotic technology has emerged as a means to decrease the learning curve and increase the availability of minimally invasive surgery to patients. A current review of the literature reveals no randomized trials evaluating the efficacy of conventional laparoscopic hysterectomy vs. robot-assisted laparoscopic hysterectomy. The investigator's aim is to address this void. The primary objective of this study is to determine whether Robot-Assisted Laparoscopic Hysterectomy is equivalent to Conventional Laparoscopic Hysterectomy with respect to operative time, blood loss, and hospital stay. The investigator's secondary objective was to assess the cost, morbidity, and mortality of each procedure.
Detailed description
See Above
Interventions
PROCEDUREConventional Laparoscopic Hysterectomy (LH)
Patients assigned to this intervention will undergo conventional laparoscopic hysterectomy, either total or supracervical.
PROCEDURERobot Assisted Hysterectomy
Patients assigned to this group will undergo Robot-Assisted Laparoscopic Hysterectomy, either total or supracervical.
Sponsors
Milton S. Hershey Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Individuals recruited into this study will be patients presenting to the Urogynecology and Minimally Invasive Surgical Group for consultation for hysterectomy.
Exclusion criteria
Individuals who are not candidates for laparoscopic surgery * Medical Condition that does not allow pneumoperitoneum * Medical Condition that does not allow proper ventilation during anesthesia * Uterine size precluding access to the uterine artery * Pelvic Organ Prolapse amendable to a vaginal approach
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Operating Time | Operating time is measured on the day of surgery after completing the procedure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intraoperative Complications | Intraoperative complications will be measured on the day of surgery after completing the procedure. | Intraoperative complications include: injury to bladder, ureters, bowel, blood vessels,and nerves AND hemorrhage |
| Perioperative Complications | Perioperative complications will be measured on the date of discharge from the hospital. | Perioperative complications include: urinary tract infections, urinary retention, ileus, myocardial infarction, atrial fibrillation, pulmonary edema, atelectasis, pneumonia, renal and cerebrovascular morbidity, thromboembolic complications (DVT and PE) |
| Estimated Blood Loss | Estimated blood loss will be measured on the day of surgery after completing the procedure. | — |
| Delayed Post-Operative Complications | Delayed post-operative complications will be measured from 2 weeks until 8 weeks after surgery, up to 56 days post-operatively. | Delayed post-operative complications include: incisional hernia formation, re-operation, vaginal evisceration |
| Costs | Cost will be assessed 8 weeks after completion of the surgery, up to 56 days post-operatively. | Costs will include the costs of pre-operative care, surgery, post-operative care, and any post-operative complications. |
| Early Postoperative Complications | Early postoperative complications will be measured on the date of discharge from the hospital until two weeks after surgery, assessed up to 14 days post-operativley. | Early postoperative complications include: pulmonary, renal, and cerebrovascular morbidity, wound and vault complications (infection, breakdown, and dehiscence); septicemia, and thromboembolic complications (DVT, PE) |
Countries
United States
Outcome results
None listed